New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
16:15 EDTTHRXTheravance initiates Phase 2 study with TD-9855 for treatment of fibromyalgia
announced today initiation of a fibromyalgia Phase 2 study with TD-9855. TD-9855 is an investigational norepinephrine and serotonin reuptake inhibitor for the treatment of central nervous system conditions such as chronic pain and Attention-Deficit/Hyperactivity Disorder.
News For THRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
16:50 EDTTHRXTheravance sees results from Salford COPD lung study in 2016
"Results from the SUMMIT chronic obstructive pulmonary disease study of 16,000 patients evaluating the impact of Relvar/Breo Ellipta on all-cause mortality among patients with COPD who have cardiovascular disease are expected to be available by year-end 2015. The Salford lung study in COPD is expected to complete by the end of 2015 with the first results expected in 2016," said the company.
16:48 EDTTHRXTheravance reports Q2 EPS (7c), consensus (6c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use